CCM
ABBV icon

Cadence Capital Management’s AbbVie ABBV Stock Holding History

Cadence Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$2.58M Sell
29,438
-7,282
-20% -$686K 0.62% 38
2020
Q2 		$3.6M Sell
36,720
-3,601
-9% -$317K 0.52% 17
2020
Q1 		$3.07M Sell
40,321
-11,008
-21% -$938K 0.52% 42
2019
Q4 		$4.54M Buy
51,329
+172
+0.3% +$14.3K 0.49% 36
2019
Q3 		$3.87M Sell
51,157
-4,614
-8% -$316K 0.55% 35
2019
Q2 		$4.06M Sell
55,771
-12,776
-19% -$1M 0.41% 42
2019
Q1 		$5.52M Sell
68,547
-42
-0.1% -$3.44K 0.5% 39
2018
Q4 		$6.32M Sell
68,589
-91,573
-57% -$8.05M 0.64% 27
2018
Q3 		$15.1M Buy
160,162
+28,037
+21% +$2.66M 0.82% 13
2018
Q2 		$12.2M Buy
132,125
+6,475
+5% +$632K 0.72% 25
2018
Q1 		$11.9M Sell
125,650
-26,147
-17% -$2.87M 0.77% 22
2017
Q4 		$14.7M Sell
151,797
-1,393
-0.9% -$131K 0.93% 11
2017
Q3 		$13.6M Sell
153,190
-28,849
-16% -$2.2M 0.85% 13
2017
Q2 		$13.2M Sell
182,039
-12,449
-6% -$837K 0.91% 11
2017
Q1 		$12.7M Buy
194,488
+16,736
+9% +$1.05M 0.87% 19
2016
Q4 		$11.1M Buy
177,752
+13,692
+8% +$836K 0.78% 30
2016
Q3 		$10.3M Sell
164,060
-22,542
-12% -$1.46M 0.76% 35
2016
Q2 		$11.6M Sell
186,602
-20,974
-10% -$1.28M 0.87% 23
2016
Q1 		$11.9M Sell
207,576
-14,771
-7% -$823K 0.83% 32
2015
Q4 		$13.2M Buy
222,347
+29,187
+15% +$1.68M 0.88% 27
2015
Q3 		$10.5M Sell
193,160
-23,256
-11% -$1.51M 0.74% 42
2015
Q2 		$14.5M Buy
216,416
+2,242
+1% +$146K 0.81% 32
2015
Q1 		$12.5M Buy
214,174
+18,735
+10% +$1.13M 0.77% 33
2014
Q4 		$12.8M Sell
195,439
-71,992
-27% -$4.54M 0.74% 37
2014
Q3 		$15.4M Buy
267,431
+37,727
+16% +$2.09M 0.81% 14
2014
Q2 		$13M Sell
229,704
-8,232
-3% -$432K 0.62% 13
2014
Q1 		$12.2M Buy
237,936
+946
+0.4% +$47.8K 0.52% 24
2013
Q4 		$12.5M Sell
236,990
-41,536
-15% -$2.04M 0.47% 44
2013
Q3 		$12.5M Buy
+278,526
New +$12.3M 0.42% 43

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Cadence Capital Management's ABBV Position: Q3 2020 in Review

Cadence Capital Management reduced its AbbVie (ABBV) stake by 20% in Q3 2020, selling an estimated $686K and leaving 29,438 shares worth $2.58M. The position accounts for 0.62% of the portfolio, ranked #38.

Cadence Capital Management first reported a position in ABBV in Q3 2013 and has held it in 29 quarters since. The position peaked at $15.4M in Q3 2014. 2,366 funds tracked by Wall St. Rank hold ABBV as of Q3 2020.

  • Cadence Capital Management held 29,438 shares of AbbVie worth $2.58M as of Q3 2020.
  • Cadence Capital Management sold 7,282 AbbVie shares in Q3 2020, an estimated $686K.
  • AbbVie made up 0.62% of Cadence Capital Management's portfolio in Q3 2020, its #38 holding.
  • Cadence Capital Management first reported a position in AbbVie in Q3 2013 and has held it in 29 quarters since.
  • Cadence Capital Management's AbbVie position peaked at $15.4M in Q3 2014.
  • 2,366 funds tracked by Wall St. Rank held AbbVie as of Q3 2020.

Based on Cadence Capital Management's 13F filing for Q3 2020, filed 16 Oct 2020.